Hydroxychloroquine is not a traditional immunosuppressant, though it does have some immunosuppressive properties. It’s more accurately described as an immunomodulator, a drug that adjusts how the immune system behaves rather than broadly shutting it down. This distinction matters because hydroxychloroquine carries a meaningfully lower risk of infections compared to conventional immunosuppressants like steroids or biologics.
How Hydroxychloroquine Affects the Immune System
Hydroxychloroquine works by sneaking into tiny compartments inside your cells called lysosomes, which act as the cell’s recycling and digestion centers. Lysosomes are normally quite acidic, with a pH around 5.0. Hydroxychloroquine raises that pH, making the environment less acidic. This seemingly small chemical change has a ripple effect on how your immune cells process threats and communicate with each other.
When lysosomes can’t maintain their usual acidity, immune cells become less efficient at breaking down proteins and presenting them to the rest of the immune system. This blunts the chain reaction that leads to inflammation. The drug also interferes with specific immune sensors called Toll-like receptors, which normally detect foreign invaders and trigger the release of inflammatory signaling molecules called cytokines. By quieting these signals, hydroxychloroquine dials down the overactive immune responses that drive autoimmune diseases.
Interestingly, the drug’s behavior depends on concentration. At lower concentrations, it acts more like a direct immunosuppressant, dampening the sensing of threats and reducing cytokine release. At higher concentrations, it shifts toward a broader immunomodulatory role, altering how immune cells process and present material. This dual nature is part of why its classification can seem confusing.
What It’s Prescribed For
Hydroxychloroquine was originally developed as an antimalarial drug and is still used to prevent and treat malaria. Its immune-calming properties led to its adoption for autoimmune conditions, and today it’s most commonly prescribed for systemic lupus erythematosus (lupus), discoid lupus (a chronic inflammatory skin condition), and rheumatoid arthritis. For lupus in particular, it’s considered a cornerstone treatment that most patients stay on long-term.
Infection Risk Compared to Stronger Immunosuppressants
One of the clearest ways to understand the difference between hydroxychloroquine and true immunosuppressants is by looking at infection rates. In a large observational study of lupus patients, steroids nearly doubled the odds of severe infection (odds ratio of 1.97), and conventional immunosuppressants increased the risk by about 56%. Hydroxychloroquine, by contrast, showed a trend toward reducing severe infections, with an odds ratio of 0.59, meaning patients on it tended to have fewer severe infections, not more.
This is a critical practical difference. Drugs like high-dose steroids and biologics suppress the immune system broadly enough that your body struggles to fight off bacteria, viruses, and fungi. Hydroxychloroquine modulates the immune system’s overreaction without leaving you nearly as vulnerable to everyday infections. Doctors sometimes use it alongside stronger immunosuppressants specifically because it can help reduce the steroid doses patients need, indirectly lowering infection risk further.
One Caveat: Vaccine Responses
Where hydroxychloroquine does behave more like an immunosuppressant is in its effect on vaccines. Because the drug alters how immune cells process and present foreign material, it can blunt the antibody response to certain vaccines. Research on chloroquine, its close chemical relative, showed significantly lower antibody responses to rabies, tetanus, and diphtheria vaccines. Hydroxychloroquine works through the same lysosomal mechanism, raising concern that it could reduce vaccine effectiveness in a similar way. If you’re on hydroxychloroquine and due for vaccinations, this is worth discussing with your doctor to plan timing appropriately.
How Long It Takes to Work (and Leave Your System)
Hydroxychloroquine is an unusually slow drug. It takes roughly six months of daily dosing to reach about 96% of its steady-state level in your blood. This means you won’t feel its full benefit for weeks to months after starting. It also means the drug lingers: its terminal half-life exceeds 40 days, so after your last dose, meaningful levels remain in your body for months. Researchers collecting blood and urine samples in pharmacokinetic studies had to continue monitoring for five months after a single dose to fully track its elimination.
Safety During Pregnancy
Unlike most drugs that modulate the immune system, hydroxychloroquine is considered safe during pregnancy. The American College of Rheumatology’s 2020 guidelines strongly recommend that all women with lupus continue taking it throughout pregnancy when possible, citing benefits for both the mother and the developing baby. This is another important distinction from conventional immunosuppressants, many of which must be stopped before or during pregnancy due to risks of birth defects.
Long-Term Side Effects and Eye Screening
The main long-term concern with hydroxychloroquine is retinal toxicity, a type of damage to the back of the eye that can affect vision. Current guidelines from the American Academy of Ophthalmology recommend keeping the daily dose at or below 5 mg per kilogram of actual body weight to minimize this risk. For a person weighing 70 kg (about 154 pounds), that means no more than 350 mg per day.
You should have a baseline eye exam including optical coherence tomography (OCT) and fundus autofluorescence (FAF) soon after starting the drug. If you have no major risk factors, annual screening can be deferred for the first five years. After that, or sooner if risk factors are present, yearly eye exams are recommended. The screening is painless and quick, involving imaging of the retina to catch early changes before they cause noticeable vision problems. Visual field tests and specialized electrical recordings of retinal function serve as secondary tools when initial imaging raises concerns.
Risk factors that warrant earlier screening include higher daily doses, kidney disease (which slows the drug’s elimination), use of the related drug tamoxifen, and pre-existing retinal conditions. The risk of retinal toxicity is low in the first five years of use but climbs with prolonged exposure, making consistent monitoring essential for anyone planning to stay on the drug long-term.